Can pressurized oxygen ease persistent concussion woes?
NCT ID NCT05173818
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether breathing pure oxygen in a pressurized chamber (hyperbaric oxygen therapy) can help adults with persistent post-concussion symptoms like headaches, fatigue, and memory problems. Twenty participants with mild traumatic brain injury received either real treatment or a sham procedure over 40 sessions. The goal was to see if the therapy improves thinking skills and reduces a brain-damage marker in the blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- hyperbaric oxygen therapy
- What this could lead to
- If it works, this could offer a new treatment option for people with long-lasting concussion symptoms that haven't improved with other therapies.
- What could go wrong
- This is a small, early-phase study with only 20 participants, so results may not apply to everyone. The sham control also involves some pressure, which could reduce the apparent benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONCUSSION POST SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Essentia Health
Fargo, North Dakota, 58103, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can eye and balance exercises help athletes recover from concussion?
- Which IV drug eases concussion symptoms best? new trial aims to find out
- Sleep therapy may ease lingering concussion symptoms
- Cooling the brain: a new hope for concussion recovery in women?
- Concussion headache drug trial stalls early